Foundation Medicine Expands Indication for FoundationOne®Liquid CDx to be used as a Companion Diagnostic for LYNPARZA®

by admin_63069 | Dec 18, 2020 | News You Can Use

Foundation Medicine’s pan tumor liquid biopsy test is now FDA-Approved to identify patients with BRCA1, BRCA2 and/or ATM alterations in metastatic castration-resistant prostate cancer who may be appropriate for treatment with LYNPARZA.